AMEX · Financial Statements

IGC Pharma, Inc. (IGC) Revenue, Earnings & Financial Statements

$0.19 AMEX: IGC Market Cap $21.93M

Data as of Nov 17, 2026 close · Statements through the quarter ended Mar 2026 · Source: Financial Modeling Prep (methodology)

IGC Pharma, Inc. most recently reported annual revenue of $1.0M, a net loss of $7.0M. Revenue declined at an average annual rate of 24.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

IGC Pharma, Inc.: Revenue fell from $6.0M in 2016 to $1.0M in 2025, a change of -83.3% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -45.6% to -585.8%, a shift of -540.2 percentage points; the most recent year shows a net loss of $7.0M.

Income Statement — 11 Years (USD millions)

Metric20162017201820192020202120222023202420252026
Revenue$6.0M$1.0M$2.0M$5.0M$4.0M$1.0M$0$1.0M$1.0M$1.0M—
Operating Expenses$9.0M$3.0M$4.0M$10.0M$11.0M$10.0M$16.0M$12.0M$11.0M$9.0M—
Operating Profit−$3.0M−$2.0M−$2.0M−$5.0M−$7.0M−$9.0M−$15.0M−$12.0M−$10.0M−$7.0M—
Operating Margin-45.6%-353.9%-81.6%-90.8%-168.6%-971.5%-3886.2%-1270.1%-728.5%-585.8%—
Other Income$0$0$0$1.0M$0$0$0$0−$3.0M$0—
Interest$0$0$0$0$0$0$0$0$0$0$0
Depreciation$1.0M$0$0$0$0$0$1.0M$1.0M$1.0M$0—
Profit Before Tax−$3.0M−$2.0M−$2.0M−$4.0M−$7.0M−$9.0M−$15.0M−$12.0M−$13.0M−$7.0M—
Tax rate (%)-0.0%-0.8%-0.0%-0.1%0.0%0.0%0.0%0.0%0.0%0.0%—
Net Profit−$3.0M−$2.0M−$2.0M−$4.0M−$7.0M−$9.0M−$15.0M−$12.0M−$13.0M−$7.0M—
EPS−$0.17−$0.07−$0.06−$0.12−$0.19−$0.21−$0.30−$0.22−$0.22−$0.09$—

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue$1.0M$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$3.0M$3.0M$3.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M$3.0M$3.0M$3.0M
Operating Profit−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$1.0M−$2.0M−$3.0M−$3.0M−$2.0M
Operating Margin-385.4%-856.0%-1469.6%-735.6%-880.9%-427.2%-730.7%-427.9%-580.8%-1517.8%-840.3%-775.4%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$2.0M−$2.0M−$6.0M−$3.0M−$2.0M−$2.0M−$2.0M−$1.0M−$2.0M−$2.0M−$1.0M−$2.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$2.0M−$6.0M−$3.0M−$2.0M−$2.0M−$2.0M−$1.0M−$2.0M−$2.0M−$1.0M−$2.0M
EPS−$0.04−$0.05−$0.09−$0.04−$0.03−$0.02−$0.02−$0.02−$0.02−$0.02−$0.01−$0.03

Over the 11 years reported for IGC Pharma, Inc., cash stood at $0 in the latest year, shareholders' equity was $139.0M, current assets covered current liabilities 0.33 times.

Balance Sheet — 11 Years (USD millions)

Metric20162017201820192020202120222023202420252026
Total Assets—$11.0M$11.0M$34.0M$29.0M$36.0M$27.0M$17.0M$10.0M$9.0M$9.0M
Current Assets—$4.0M$3.0M$27.0M$18.0M$24.0M$15.0M$6.0M$4.0M$3.0M$1.0M
Cash—$1.0M$2.0M$26.0M$7.0M$15.0M$10.0M$3.0M$1.0M$0$0
Inventory—$0$0$0$4.0M$7.0M$4.0M$3.0M$2.0M$1.0M$1.0M
Receivables—$1.0M$1.0M$0$0$0$1.0M$0$0$0$0
Fixed Assets—$1.0M$6.0M$6.0M$10.0M$11.0M$10.0M$9.0M$4.0M$3.0M$2.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0$0
Investments$0$8.0M$1.0M$1.0M$5.0M$0$0$0$1.0M$1.0M$0
Other Assets—$0$0$0$0$0$0$0$0$0$0
Total Liabilities—$4.0M$3.0M$1.0M$2.0M$3.0M$3.0M$2.0M$3.0M$2.0M$3.0M
Current Liabilities—$1.0M$2.0M$1.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$3.0M
Borrowings$0$3.0M$2.0M$0$1.0M$1.0M$1.0M$0$0$0$0
Other Liabilities—$1.0M$1.0M$1.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$3.0M
Equity—$0$64.0M$94.0M$95.0M$110.0M$116.0M$119.0M$124.0M$131.0M$139.0M
Reserves—$7.0M$8.0M$34.0M$27.0M$33.0M$24.0M$15.0M$7.0M$6.0M$6.0M

For IGC Pharma, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was $0; free cash flow was positive in 0 of 11 years.

Cash Flow Statement — 11 Years (USD millions)

Metric20162017201820192020202120222023202420252026
Operating Cash Flow$0−$1.0M−$2.0M−$3.0M−$9.0M−$11.0M−$7.0M−$7.0M−$5.0M−$5.0M—
Investing Cash Flow$0$0−$1.0M$0−$14.0M$2.0M−$2.0M−$1.0M−$1.0M−$1.0M—
Financing Cash Flow$0$0$0$0$0$0$0$0$0$0—
Net Cash Flow$1.0M−$1.0M$1.0M$24.0M−$18.0M$7.0M−$4.0M−$7.0M−$2.0M−$1.0M—
Free Cash Flow$0−$2.0M−$2.0M−$3.0M−$13.0M−$12.0M−$8.0M−$8.0M−$6.0M−$5.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.17
EV / EBITDA-2.70
FCF Yield-27.31%
Quick Ratio0.21
Interest Coverage—
Return 1Y-50.00%
Return 3Y-40.00%
Return 5Y-88.16%

IGC Pharma, Inc. (IGC) financials — frequently asked questions

What is IGC Pharma, Inc.'s annual revenue?

IGC Pharma, Inc. (IGC) reported annual revenue of $1.0M in its most recent fiscal year.

What is IGC Pharma, Inc.'s net profit?

IGC Pharma, Inc. (IGC) reported a net loss of $7.0M in its most recent fiscal year.

What is IGC EV/EBITDA?

IGC Pharma, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.70. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
IGC Overview IGC Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.